CTOs on the Move


 
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.xellia.com
  • 8841 Wadford Drive
    Raleigh, NC USA 27616
  • Phone: 919.327.5500

Executives

Name Title Contact Details

Similar Companies

IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx`s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx`s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions. IntelGenx`s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx`s state-of-the-art manufacturing facility offers full service by providing lab-scale through to pilot- and commercial-scale production.

Precision BioLogic

Precision BioLogic is a Dartmouth, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioCareSD

BioCareSD is a specialty distributor of biological products for hemophilia, thrombophilia, immunology, critical care, and ALS. They are committed to providing customer-oriented solutions, unmatched service levels, and a unique distribution network to e...

Johnson & Johnson Vision

Learn about how Johnson & Johnson Vision is committed to addressing the world-wide problems of vision impairment through prevention and treatment.

Civica Rx

Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for a pack of five pre-filled pens, regardless of insurance status.